MA51433A - Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase - Google Patents
Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinaseInfo
- Publication number
- MA51433A MA51433A MA051433A MA51433A MA51433A MA 51433 A MA51433 A MA 51433A MA 051433 A MA051433 A MA 051433A MA 51433 A MA51433 A MA 51433A MA 51433 A MA51433 A MA 51433A
- Authority
- MA
- Morocco
- Prior art keywords
- kinase inhibitor
- piperidine derivative
- aminomethyl piperidine
- aminomethyl
- derivative
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- DBMHTLOVZSDLFD-UHFFFAOYSA-N piperidin-1-ylmethanamine Chemical class NCN1CCCCC1 DBMHTLOVZSDLFD-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170183062A KR102577242B1 (ko) | 2017-12-28 | 2017-12-28 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51433A true MA51433A (fr) | 2021-04-07 |
Family
ID=67067897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051433A MA51433A (fr) | 2017-12-28 | 2018-12-28 | Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11407754B2 (fr) |
| EP (1) | EP3733674B1 (fr) |
| JP (1) | JP7024091B2 (fr) |
| KR (1) | KR102577242B1 (fr) |
| CN (1) | CN111527088B (fr) |
| AU (1) | AU2018394996B2 (fr) |
| BR (1) | BR112020013237A2 (fr) |
| CA (1) | CA3085160C (fr) |
| CL (1) | CL2020001749A1 (fr) |
| CO (1) | CO2020007156A2 (fr) |
| DO (1) | DOP2020000111A (fr) |
| EC (1) | ECSP20035588A (fr) |
| ES (1) | ES2924225T3 (fr) |
| MA (1) | MA51433A (fr) |
| MX (1) | MX2020006798A (fr) |
| MY (1) | MY196572A (fr) |
| NZ (1) | NZ765152A (fr) |
| PE (1) | PE20210549A1 (fr) |
| RU (1) | RU2756505C1 (fr) |
| SA (1) | SA520412334B1 (fr) |
| SG (1) | SG11202004916YA (fr) |
| TN (1) | TN2020000081A1 (fr) |
| WO (1) | WO2019132561A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020002265A2 (pt) | 2017-08-01 | 2020-07-28 | Theravance Biopharma R&D Ip, Llc | compostos pirazólicos e triazólicos bicíclicos como inibidores de jak quiinase |
| TN2020000082A1 (en) | 2017-12-28 | 2022-01-06 | Dae Woong Pharma | Oxy-fluoropiperidine derivative as kinase inhibitor |
| KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
| JP2022518741A (ja) | 2019-01-23 | 2022-03-16 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ＪＡＫキナーゼ阻害剤としてのイミダゾ［１，５－ａ］ピリジン、１，２，４－トリアゾロ［４，３－ａ］ピリジンおよびイミダゾ［１，５－ａ］ピラジン |
| KR102228668B1 (ko) * | 2019-10-08 | 2021-03-17 | (주)부흥산업사 | 메틸피퍼리딘 아미노피롤로 피리미딘의 제조방법 |
| CN112824381B (zh) * | 2019-11-21 | 2024-04-26 | 广东东阳光药业股份有限公司 | 一种哌啶胺的制备方法 |
| CN114901659A (zh) | 2019-11-26 | 2022-08-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的稠合嘧啶吡啶酮化合物 |
| WO2021147952A1 (fr) * | 2020-01-21 | 2021-07-29 | 江苏先声药业有限公司 | Composé pyrimidopyrrole |
| CN113214265B (zh) * | 2020-01-21 | 2023-07-07 | 江苏先声药业有限公司 | 嘧啶并五元环类化合物 |
| WO2021147953A1 (fr) * | 2020-01-21 | 2021-07-29 | 江苏先声药业有限公司 | Dérivé cyclique pyrimidino à cinq chaînons et application correspondante |
| TW202214643A (zh) * | 2020-09-22 | 2022-04-16 | 大陸商江蘇先聲藥業有限公司 | 嘧啶并吡咯類化合物 |
| CN114315838A (zh) * | 2020-09-30 | 2022-04-12 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
| WO2023165562A1 (fr) * | 2022-03-02 | 2023-09-07 | 南京明德新药研发有限公司 | Composé hétérocyclique contenant de l'azote et son utilisation |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| EP3311818A3 (fr) | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibiteurs de tyrosine-kinase de bruton pour le traitement de tumeurs solides |
| WO2010129053A2 (fr) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Inhibiteurs d'egfr et procédés de traitement de troubles |
| SG186378A1 (en) | 2010-06-23 | 2013-01-30 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
| BR112014006840A2 (pt) * | 2011-09-22 | 2017-04-04 | Pfizer | derivados de pirrolopirimidina e purina |
| EP3170825B1 (fr) | 2012-08-06 | 2019-04-10 | ACEA Biosciences Inc. | Pyrrolopyridines utiles en tant qu'inhibiteurs de protéines kinases |
| DK2917138T3 (en) | 2012-11-08 | 2019-04-15 | Compac Tech Limited | ARTICLE CARRIER FOR A SORTING DEVICE |
| CN105188704B (zh) | 2013-01-16 | 2017-09-19 | 西格诺药品有限公司 | 被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法 |
| EP3048105A4 (fr) | 2013-09-18 | 2017-05-17 | Beijing Hanmi Pharmaceutical Co., Ltd. | Composé inhibiteur d'activités de kinase de btk et/ou de jak3 |
| JP6192839B2 (ja) | 2013-12-05 | 2017-09-06 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、およびピロロ［２，３−ｄ］ピリジニルアクリルアミド |
| CN105732637B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| JP2018537502A (ja) * | 2015-12-16 | 2018-12-20 | サウザーン リサーチ インスチチュート | ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法 |
| SG11201811470PA (en) | 2016-06-30 | 2019-01-30 | Daewoong Pharmaceutical Co Ltd | Pyrazolopyrimidine derivatives as kinase inhibitor |
| CN106432294B (zh) | 2016-09-19 | 2018-01-30 | 淮北师范大学 | 发光配合物及其制备方法 |
| KR102032418B1 (ko) | 2017-06-15 | 2019-10-16 | 한국화학연구원 | 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물 |
| KR102577241B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
| TN2020000082A1 (en) | 2017-12-28 | 2022-01-06 | Dae Woong Pharma | Oxy-fluoropiperidine derivative as kinase inhibitor |
| KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
-
2017
- 2017-12-28 KR KR1020170183062A patent/KR102577242B1/ko active IP Right Grant
-
2018
- 2018-12-28 US US16/770,213 patent/US11407754B2/en active Active
- 2018-12-28 TN TNP/2020/000081A patent/TN2020000081A1/en unknown
- 2018-12-28 MX MX2020006798A patent/MX2020006798A/es unknown
- 2018-12-28 JP JP2020534937A patent/JP7024091B2/ja active Active
- 2018-12-28 AU AU2018394996A patent/AU2018394996B2/en active Active
- 2018-12-28 CA CA3085160A patent/CA3085160C/fr active Active
- 2018-12-28 SG SG11202004916YA patent/SG11202004916YA/en unknown
- 2018-12-28 CN CN201880083535.6A patent/CN111527088B/zh active Active
- 2018-12-28 EP EP18897615.3A patent/EP3733674B1/fr active Active
- 2018-12-28 BR BR112020013237-3A patent/BR112020013237A2/pt unknown
- 2018-12-28 MA MA051433A patent/MA51433A/fr unknown
- 2018-12-28 ES ES18897615T patent/ES2924225T3/es active Active
- 2018-12-28 WO PCT/KR2018/016813 patent/WO2019132561A1/fr unknown
- 2018-12-28 PE PE2020000794A patent/PE20210549A1/es unknown
- 2018-12-28 RU RU2020124575A patent/RU2756505C1/ru active
- 2018-12-28 NZ NZ765152A patent/NZ765152A/en unknown
- 2018-12-28 MY MYPI2020002466A patent/MY196572A/en unknown
-
2020
- 2020-06-10 DO DO2020000111A patent/DOP2020000111A/es unknown
- 2020-06-11 CO CONC2020/0007156A patent/CO2020007156A2/es unknown
- 2020-06-25 SA SA520412334A patent/SA520412334B1/ar unknown
- 2020-06-26 CL CL2020001749A patent/CL2020001749A1/es unknown
- 2020-06-29 EC ECSENADI202035588A patent/ECSP20035588A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3085160C (fr) | 2021-12-07 |
| MX2020006798A (es) | 2020-09-03 |
| SG11202004916YA (en) | 2020-06-29 |
| MY196572A (en) | 2023-04-19 |
| SA520412334B1 (ar) | 2022-11-03 |
| PE20210549A1 (es) | 2021-03-17 |
| US11407754B2 (en) | 2022-08-09 |
| BR112020013237A2 (pt) | 2020-12-01 |
| WO2019132561A1 (fr) | 2019-07-04 |
| EP3733674A1 (fr) | 2020-11-04 |
| KR102577242B1 (ko) | 2023-09-11 |
| CL2020001749A1 (es) | 2020-11-06 |
| TN2020000081A1 (en) | 2022-01-06 |
| CN111527088B (zh) | 2022-12-30 |
| KR20190080541A (ko) | 2019-07-08 |
| WO2019132561A8 (fr) | 2020-06-11 |
| EP3733674B1 (fr) | 2022-06-29 |
| DOP2020000111A (es) | 2020-09-30 |
| CN111527088A (zh) | 2020-08-11 |
| AU2018394996A1 (en) | 2020-06-25 |
| AU2018394996A2 (en) | 2020-07-16 |
| NZ765152A (en) | 2024-02-23 |
| ES2924225T3 (es) | 2022-10-05 |
| JP2021507923A (ja) | 2021-02-25 |
| CO2020007156A2 (es) | 2020-06-19 |
| RU2756505C1 (ru) | 2021-10-01 |
| US20210188854A1 (en) | 2021-06-24 |
| EP3733674A4 (fr) | 2021-06-09 |
| JP7024091B2 (ja) | 2022-02-22 |
| CA3085160A1 (fr) | 2019-07-04 |
| ECSP20035588A (es) | 2020-07-31 |
| AU2018394996B2 (en) | 2021-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51433A (fr) | Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase | |
| MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
| MA51429A (fr) | Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| MA54547A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
| MA54546A (fr) | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a | |
| MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| MA51431A (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
| MA42990A (fr) | Composés utiles en tant qu'immunomodulateurs | |
| MA40774A (fr) | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 | |
| MA55194A (fr) | Composés hétérocycliques en tant qu'immunomodulateurs | |
| MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
| BR112017027339A2 (pt) | derivados de piperidina 1,4-substituída | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| MA47573A (fr) | Inhibiteurs de dihydrobenzofurane glycosidase substitués | |
| MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac | |
| MA52123A (fr) | Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2 | |
| MA47736A (fr) | Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 | |
| MA53643A (fr) | Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 | |
| FR3034987B1 (fr) | Composition a base de trans-resveratrol ou d'un derive de trans-resveratrol | |
| DK3405287T3 (da) | Slidbeskyttelseselement til en fragmenteringsmaskine | |
| MA51284A (fr) | Dérivés d'oxadiazole en tant qu'inhibiteurs de kinase rho |